Epacadostat in combination with durvalumab is safe and effective for advanced solid tumours

A recent study demonstrated the safety, tolerability and efficacy of epacadostat in combination with durvalumab in adult patients with advanced solid tumours. This study was published in the journal, Cancer.
The study was an open-label, phase 1/2 ECHO-203 study which evaluated the safety, tolerability, and efficacy of epacadostat (indoleamine 2,3-dioxygenase inhibitor) in combination with durvalumab (antiprogrammed cell death protein 1 monoclonal antibody).
The most common treatment-related adverse events reported were fatigue, nausea, decreased appetite, pruritus, maculopapular rash, and diarrhea. Higher objective response rate was observed in immune checkpoint inhibitor (CPI)-native patients (16.1%) compared with patients who had received previous CPI (4.1%). Moreover, the 300-mg epacadostat dose showed evidence of kynurenine level modulation.
Based on the results of the study, it can be concluded that the epacadostat in addition with durvalumab was beneficial in patients with advanced solid tumours. Based on the evaluation of kynurenine concentration from baseline it is suggested that >300 mg epacadostat twice daily will provide sufficient drug effect.